Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Biol Macromol ; 35(1-2): 63-9, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15769517

RESUMO

Depolymerisation by oxytetracycline (OTC) as well as the progressive cleavage of hyaluronic acid induced by ultrasound was investigated in nine commercially available hyaluronic polymers. Sample solutions differed in molecular weight, from 500 to 7000 kDa, and in their source. The hyaluronic acid concentration in each sample was analysed by HPLC. The concentration range was over 8.39-10.18 mg ml(-1) in samples with a nominal concentration of 1%, and 14.05 mg ml(-1) in one sample with a nominal concentration of 1.5%. It was found that stability was dependent on both molecular weight and the concentration of the samples. The rheological parameters n (power law index) and K (consistency coefficient) were good predictors regarding the degradation behaviour. Although many factors are involved in obtaining a therapeutic response, the results obtained in this work support the notion that both mechanical and chemical degradation are reduced in hyaluronate solutions with low molecular weight, the final concentration of the product being a critical factor.


Assuntos
Materiais Biocompatíveis/química , Ácido Hialurônico/química , Oxitetraciclina/química , Calibragem , Cromatografia , Cromatografia Líquida de Alta Pressão , Elasticidade , Modelos Lineares , Mecânica , Peso Molecular , Polímeros/química , Pressão , Reologia , Sonicação , Temperatura , Fatores de Tempo , Viscosidade
2.
J Pharm Pharmacol ; 55(6): 757-64, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12841935

RESUMO

Albendazole is a broad spectrum anthelmintic drug widely used in human and veterinary medicine. Intestinal and hepatic albendazole metabolism leads to albendazole sulfoxide (active metabolite) and albendazole sulfone (inactive metabolite) formation. Microsomal sulfonase activity can be abolished by in-vitro interaction with clotrimazole and pharmacokinetic studies confirm this interaction. After albendazole incubation, albendazole sulfone formation was completely inhibited by 50 microM clotrimazole in intestinal incubations and a 50% inhibition was observed in hepatic incubations. The lower inhibition constant (K(i)) value observed in the intestinal incubations (9.4 +/- 1.0 microM) compared with the hepatic counterparts (23.3 +/- 15.8 microM) pointed to a greater affinity of the enzymatic systems in the intestine. Regarding the formation of albendazole sulfoxide, an inhibition close to 50% was observed in liver and intestine at 10 microM clotrimazole. The pharmacokinetic parameters obtained following the oral co-administration of albendazole sulfoxide and clotrimazole corroborated the in-vitro inhibition of albendazole sulfone formation, since the ratio of the area under the plasma concentration-time curves for the sulfoxide/sulfone (AUC(ABZSO)/AUC(ABZSO2)) was significantly higher (38.1%). In addition, the AUC and C(max) for albendazole sulfone were significantly lower. The effect of clotrimazole was also studied after prolonged treatment. Hepatic microsomal metabolism of albendazole was induced after 10 days of clotrimazole administration, with significant increases in formation of albendazole sulfoxide (40%) and sulfone (27%). These results offer further insight into the metabolism of benzimidazole drugs and highlight the difficulty involved in human therapy with these anthelmintics, since after prolonged treatment the drug interactions are affected differentially.


Assuntos
Albendazol , Albendazol/análogos & derivados , Anti-Helmínticos , Antifúngicos/farmacologia , Clotrimazol/farmacologia , Fígado/efeitos dos fármacos , Administração Oral , Albendazol/sangue , Albendazol/metabolismo , Albendazol/farmacocinética , Animais , Anti-Helmínticos/sangue , Anti-Helmínticos/metabolismo , Anti-Helmínticos/farmacocinética , Área Sob a Curva , Biotransformação , Interações Medicamentosas , Meia-Vida , Fígado/enzimologia , Fígado/metabolismo , Masculino , Ratos , Ratos Wistar
3.
J Pharm Biomed Anal ; 31(4): 639-45, 2003 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-12644190

RESUMO

A simple, rapid and sensitive high-performance liquid chromatographic (HPLC) method has been developed to quantify Ivermectin (IVM) in plasma using an isocratic system with fluorescence detection. The method included a fast liquid phase extraction using cold methanol. HPLC separation was carried out by reversed phase chromatography with a mobile phase composed of methanol:acetonitrile:water with 0.2% acetic acid (45:50:5 v/v/v), pumped at flow rate of 2 ml min(-1). Fluorescence detection was performed at 365 nm (excitation) and 475 nm (emission). The calibration curve for IVM was linear from 0.25 to 100 ng ml(-1). The validation method yielded good results regarding linearity, precision, accuracy, specificity and recoveries. The values of the limit of detection (LOD) and limit of quantification (LOQ) were 0.032 and 0.167 ng ml(-1), respectively.


Assuntos
Ivermectina/sangue , Cromatografia Líquida de Alta Pressão/métodos , Ivermectina/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...